Treatment of atrial fibrilation

Endosense SA
route de Satigny 42
1217 Meyrin Geneva

Auf Karte anzeigen
Firmenbeschrieb
Founded in 2003, Endosense develops and commercializes solutions to enable the adoption of percutaneous catheter ablation for the treatment of atrial fibrillation (AF). With 6 million patients impacted, AF is the most prevalent cardiac rhythm disorder in which the upper chambers of the heart beat ineffectively due to abnormal electrical activity. The Company's lead product is a Force Sensor catheter, TactiCath™, which measures the force the catheter is exerting on the beating heart wall. TactiCath™ has the potential to increase the effectiveness and the safety profile of percutaneous catheter ablation.

Gründungsjahr
2003
 
Rechtsform
Gesellschaft mit beschränkter Haftung (GmbH)
 
Anzahl Mitarbeiter
20
 


Schlüsselwörter
atrial fibrilation
Eintrag erstellt: 16.10.2006, Letzte Änderung: 16.10.2006